Amarin (AMRN)
(Real Time Quote from BATS)
$0.60 USD
0.00 (0.55%)
Updated Sep 19, 2024 11:24 AM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 281 - 300 ( 365 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
NCE Decision Not Expected in Upcoming Orange Book Update; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa NCE Determination by the FDA Delayed
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
No It''s Not An Echo, Another Patent for Vascepa
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 9, 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
When it Rains, it Pours, Another Patent Win; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Two More Vascepa Patents Allowed, Including Key ''889; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Announces Allowance of ''145 Patent Application from MARINE Family; Additional NOAs Expected Soon; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
145 Patent Allowed; Reiterate Buy and $26 Price Target
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 2, 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
2Q12 Results; The 3 Path Puzzle for Vascepa
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Less Aggressive Tone on Self-Launch Should Calm Nerves; Timing of NCE Decision not a Lock; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.